Trial Profile
Skeletal muscle-derived cell implantation for the treatment of fecal incontinence: a multicenter, randomized, double-blind, placebo controlled, parallel-group, dose-finding clinical study
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Nov 2020
Price :
$35
*
At a glance
- Drugs ICEF 15 (Primary)
- Indications Faecal incontinence
- Focus Therapeutic Use
- Acronyms STEFFI
- Sponsors Innovacell Biotechnologie GmbH
- 22 May 2020 Status changed from recruiting to discontinued.
- 27 Mar 2020 This trial has been discontinued in Bulgaria
- 13 Sep 2017 The study has been discontinued in Czech Republic (End date: 2017-08-21)